Immunosuppessants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including Tricor, there is a risk that an interaction will lead to deterioration of renal function. The benefits and risks of using Tricor (fenofibrate tablets) with immunosuppressants and other potentially nephrotoxic agents should be carefully considered, and the lowest effective dose employed and renal function monitored.
Since bile acid binding resins may bind other drugs given concurrently, patients should take Tricor at least 1 hour before or 4 to 6 hours after a bile acid binding resin to avoid impeding its absorption.
Cases of myopathy, including rhabdomyolysis, have been reported with fenofibrates co-administered with colchicine, and caution should be exercised when prescribing fenofibrate with colchicine.
Safety in pregnant women has not been established. There are no adequate and well controlled studies of fenofibrate in pregnant women. Fenofibrate should be use< 0. There have been postmarketing and clinical test reports of intense reductions in HDL cholesterol degrees (as reduced as 2 mg/dL)happening in diabetic and non-diabetic people initiated on fibrate therapy. The decrease in HDL-C is mirrored by a reduction
in apolipoprotein A1. This decrease has actually been reported to take place within 2 weeks to years after initiation of fibrate therapy. The HDL-C levels continue to be depressed until fibrate treatment has been taken out; the response to drawback of fibrate treatment is rapid as well as sustained. The medical value of this decline in HDL-C is unidentified. It is suggested that HDL-C degrees be examined within the very first few months after commencement of fibrate therapy. If a significantly depressed HDL-C degree is sensed, fibrate treatment must be withdrawn, as well as the HDL-C degree kept an eye on until it has actually gone back to baseline, and fibrate therapy ought to not be re-initiated. Because professional researches are carried out under widely differing conditions, adverse reaction rates noted in
the professional researches of a drug could not be straight compared with rates in the medical research studies of another medicine and may not reflect the rates noted in method.